PT  - JOURNAL ARTICLE
AU  - McGarry, Andrew
AU  - Auinger, Peggy
AU  - Kieburtz, Karl D.
AU  - Bredlau, Amy-Lee
AU  - Hersch, Steven M.
AU  - Rosas, H. Diana
TI  - Suicidality Risk Factors Across the CARE-HD, 2CARE, and CREST-E Clinical Trials in Huntington Disease
AID  - 10.1212/CPJ.0000000000001161
DP  - 2022 Apr 01
TA  - Neurology: Clinical Practice
PG  - 131--138
VI  - 12
IP  - 2
4099  - http://cp.neurology.org/content/12/2/131.short
4100  - http://cp.neurology.org/content/12/2/131.full
AB  - Background and Objectives Suicidality is a common concern in the routine care of persons with Huntington disease (HD) and for the many participants in HD clinical trials. In a previous analysis, we identified baseline and time-dependent factors associated with suicidal ideation and attempts from 2CARE, a large, randomized, double-blind clinical trial.Methods The present analysis extends our prior methodology to 2 other large interventional HD clinical trials, CARE-HD and CREST-E.Results We observed relationships across studies between suicidality events and prior suicidal ideation at baseline, antidepressant/anxiolytic use, chorea, increasing age, and several domains in the Unified Huntington Disease Rating Scale (UHDRS) Behavioral Assessment (depressed mood, low self-esteem, aggression, and active suicidality).Discussion These data may form the basis for a subscale of demographic and UHDRS items with the potential for prospectively identifying suicidality risk in HD clinics and clinical trials.Trial Registration Information 2CARE and CREST are registered at clinicaltrials.gov. 2CARE NCT00608881, registered February 6, 2008; first enrollment March 2008. CREST-E NCT00712426, registered July 10, 2008; first enrollment September 2009. CARE-HD, not registered; first enrollment July 1997.